Buprenorphine, Urine Screen with Reflex to Quantitation
Also known as: BUPR RFX U
Use
This test is useful for general screening in contexts of compliance and/or abuse. The screen with reflex testing is the preferred method for ruling out buprenorphine exposure. If a specimen screens positive, it undergoes confirmation and quantitation testing by liquid chromatography-tandem mass spectrometry, which provides specific identification and quantification of buprenorphine and its metabolites.
Special Instructions
Not provided.
Limitations
Presumptive results may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or diluted/adulterated urine. The concentration at which the screening test detects a drug or metabolite varies within a drug class. Limitations of testing may result in false negatives or positives.
New York Approved
Methodology
Immunoassay
Biomarkers
Buprenorphine
Analyte
LOINC Codes
- 54247-2 - Drug screen comment Ur-Imp
- 93494-3 - Buprenorphine Ur Ql Scn
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4 mL
Minimum Volume
2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube (Min: 2 mL).
Storage Instructions
Room temperature.
Causes for Rejection
Unknown fluids, pharmaceutical preparations, and breast milk. Specimens exposed to repeated freeze/thaw cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |
Other tests from different labs that may be relevant